# US 2014/0155498 A1 · Method of Manufacture of Stable Liquid Coagulation Factors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155498 A1
- Document ID: US20140155498A1
- Status: Published application
- Kind: A1
- Application number: 14/175,077
- Filed: 2014-02-07
- Published: 2014-06-05
- Earliest claimed: 2012-10-12
- Inventors: Leon Wortham
- Web page: https://patentgrep.com/patent/US20140155498A1

## CPC

- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A diagnostic or therapeutic formulation of stable liquid coagulation factors comprises at least one coagulation factor, at least one stabilizer, and optional additives. The stabilizer is either amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin, or a blend of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin. A preferred additive is the zwitterionic buffer 3-[N-tris(hydroxymethyl)methylamino)-2-hydroxypropane sulfonic acid (TAPSO). The stable liquid coagulation factors can be used as reagents and controls in plasma clotting assays. In addition the therapeutic formulation can be used for factor replacement therapy. The stable liquid clotting factors are made by combining the coagulation factor(s), stabilizer(s), and additive(s) in a liquid carrier and sterilizing the mixture. Coagulation factors can be concentrated by selective precipitation from plasma. In addition, the clotting activity of the formulation can be adjusted by adding a factor concentrate to a less concentrated formulation.

## Claims

### Claim 1

A method for preparing a composition of matter, comprising:
(a) combining at least one stabilizer, a zwitterionic buffer and at least one coagulation factor in a liquid carrier to form a buffered solution, wherein the coagulation factor is a component in a cascade pathway that leads to clot formation and the stabilizer is selected from the group consisting of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin, present in an amount sufficient to retard the degradation of the coagulation factor for at least one month when the composition of matter is stored at 2° C. to 8° C.;
(b) adjusting the pH of the solution to between about 6 to about 9; and
(c) sterilizing the solution.

### Claim 2

A method for preparing a composition of matter containing at least one coagulation factor, comprising the steps of:
(a) mixing a liquid containing at least one coagulation factor with barium chloride in an amount sufficient to form a first precipitate and a first supernatant;
(b) isolating the first precipitate from the first supernatant;
(c) resuspending the first precipitate in a solution of ammonium sulfate to form a second precipitate and a second supernatant;
(d) separating the second supernatant from the second precipitate;
(e) increasing the concentration of ammonium sulfate in the second supernatant to form a third precipitate;
(f) collecting the third precipitate;
(g) forming a suspension of the third precipitate in dialysis buffer, the dialysis buffer comprising:
(i) a liquid carrier;
(ii) at least one stabilizer, wherein the stabilizer is selected from the group consisting of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin; and
(iii) at least one additive selected from the group consisting of a zwitterionic buffer, an antibiotic agent, and sodium citrate; and
(h) dialyzing the suspension against dialysis buffer, wherein the suspension is held within a dialysis membrane capable of retaining the coagulation factor.

### Claim 3 (depends on 2)

A factor concentrate prepared according to the method of claim 2.

### Claim 4 (depends on 3)

A method of preparing a coagulation control, comprising the steps of:
(a) combining at least one stabilizer, a zwitterionic buffer and at least one coagulation factor in a liquid carrier to form a buffered solution, wherein the stabilizer is selected from the group consisting of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin, the stabilizer being present in an amount sufficient to retard the degradation of the coagulation factor for at least one month when the solution is stored at 2° C. to 8° C.; and
(b) testing the buffered solution in a clotting time assay, and, if needed, adding to the solution the factor concentrate of claim 3 in an amount sufficient to adjust the clotting time assay within a desired range.

### Claim 5 (depends on 4)

A coagulation control prepared according to the method of claim 4.

### Claim 6

An assay for detecting clot formation comprising:
(a) combining a sample and a reagent, wherein the reagent is a composition of matter comprising a phospholipid coagulation factor in the liquid carrier that mediates a cascade pathway that leads to clot formation selected from the group consisting essentially of thromboplastin cephaloplastin, cephalin, and soy phosphatides; and at least one stabilizer for the phospholipid coagulation factor in the liquid carrier selected from the group consisting of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin, the stabilizer being present in an amount sufficient to retard the degradation of the coagulation factor for at least one month when the composition of matter is stored at 2° C. to 8° C.;
(b) initiating clot formation when calcium ions are introduced with the sample and reagent; and
(c) determining a sample clotting time.

### Claim 7 (depends on 6)

An assay according to claim 6, wherein the combining step (a) further comprises combining a factor deficient plasma with the sample and reagent, wherein the factor deficient plasma comprises:
(i) plasma selected from the group consisting of Factor II deficient, Factors II and VII deficient, Factors II, VII, and X deficient, Factor V deficient, Factor VII deficient, Factors VII and X deficient, Factor VIII deficient, Factor IX deficient, Factor X deficient, Factor XI deficient, Factor XII deficient, Factor XIII deficient, high molecular weight kininogen deficient, plasminogen activator inhibitor deficient, t-plasminogen activator deficient, prekallikrein deficient, protein C deficient, protein S, and protein X deficient plasmas; and
(ii) at least one stabilizer for the plasma, wherein the stabilizer is selected from the group consisting of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin, the stabilizer being present in an amount sufficient to retard the degradation of the plasma for at least one month when the plasma is stored at 2° C. to 8° C.

### Claim 8 (depends on 6)

An assay according to claim 6 further comprising:
(a) combining a control with a reagent, the control comprising;
(i) a liquid carrier;
(ii) a plurality of coagulation factors, wherein the coagulation factors are components in a cascade pathway that leads to clot formation; and
(iii) a stabilizer for the coagulation factors in the liquid carrier, wherein the stabilizer is selected from the group consisting of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin, the stabilizer being present in an amount sufficient to retard the degradation of the coagulation factors for at least one month when the control is stored at 2° C. to 8° C.;
(b) initiating clot formation when calcium ions are introduced with the control and the reagent;
(c) determining a control clotting time; and
(d) relating the sample clotting time to the control clotting time to determine whether the sample clotting time falls within a select range.

### Claim 9 (depends on 3)

An assay for detecting clot formation comprising:
(a) combining a sample and a reagent, wherein the reagent is selected from the group consisting of thromboplastin, cephaloplastin, cephalin, and soy phosphatides;
(b) initiating clot formation when calcium ions are introduced with the sample and reagent; and
(c) determining a sample clotting time;
(d) combining a control with a reagent, wherein the control is the coagulation control prepared by:
(i) combining at least one stabilizer, a zwitterionic buffer and at least one coagulation factor in a liquid carrier to form a buffered solution, wherein the stabilizer is selected from the group consisting of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin and gum, the stabilizer being present in an amount sufficient to retard the degradation of the coagulation factor for at least one month when the solution is stored at 2° C. to 8° C.; and
(ii) testing the buffered solution in a clotting time assay, and, if needed, adding to the solution the factor concentrate of claim 3 in an amount sufficient to adjust the clotting time assay within a desired range;
(e) initiating clot formation when calcium ions are introduced with the control and the reagent;
(f) determining a control clotting time; and
(g) relating the sample clotting time to the control clotting time to determine whether the sample clotting time falls within a select range.

### Claim 10

A test kit for use in an assay that detects clot formation, the test kit comprising:
(a) a first container comprising a reagent, wherein the reagent is a composition of matter comprising;
(b) combining a sample and a reagent, wherein the reagent is a composition of matter comprising aphospholipid coagulation factor in the liquid carrier that mediates a cascade pathway that leads to clot formation selected from the group consisting essentially of thromboplastin, cephaloplastin, cephalin, and soy phosphatides; and at least one stabilizer for the phospholipid coagulation factor in the liquid carrier selected from the group consisting of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin, the stabilizer being present in an amount sufficient to retard the degradation of the coagulation factor for at least one month when the composition of matter is stored at 2° C. to 8° C.; and
(c) at least one other container comprising a control.

### Claim 11 (depends on 10)

A test kit according to claim 10 wherein the control comprises:
(a) a liquid carrier;
(b) a plurality of coagulation factors in the liquid carrier, wherein the coagulation factors are components in a cascade pathway that leads to clot formation; and
(c) at least one stabilizer for the coagulation factors in the liquid carrier, wherein the stabilizer is selected from the group consisting of amylopectin, galatomannan polysaccharide, agarose, agaropectin, and gelatin, the stabilizer being present in an amount sufficient to retard the degradation of the coagulation factors for at least one month when the control is stored at 2° C. to 8° C.

### Claim 12 (depends on 5)

A test kit for use in an assay that detects clot formation, the test kit comprising:
(a) a first container comprising a reagent, wherein the reagent is selected from the group consisting essentially of thromboplastin, cephaloplastin, cephalin, and soy phosphatides; and
(b) at least one other container comprising a control, wherein the control is the coagulation control of claim 5.

### Claim 13 (depends on 2)

A method of replacing a coagulation factor in vivo comprising administering by intravenous infusion, an effective dose of a factor concentrate wherein the factor concentrate is prepared according to the method of claim 2